Premenstrual Dysphoric Disorder recognized in new WHO International Classification of Diseases ICD-11
Stockholm, June 11, 2019: Premenstrual dysphoric disorder (PMDD) has been given its own classification code and for the first time classified clearly as a gynaecological, not mental, disease in the WHO’s new International Classification of Diseases, ICD-11. “This is a crucial step forward for future diagnosis, treatment and reimbursement of our lead indication” says CEO…
(Stockholm, June 4, 2019) Asarina Pharma AB (publ) today announces that it will, pursuant to the authorisation granted by the Annual General Meeting on 8 May 2019, issue 246,434 new shares to Ergomed plc (“Ergomed”), the CRO carrying out its Phase IIb PMDD study.
PMS & PMDD in spotlight at Gothenburg event for International Menstrual Hygiene Day
(Stockholm May 23, 2019) Valuable knowledge about PMS & PMDD will be shared at the University of Gothenburg on May 28 at a public evening of talks, lectures and Q&A. Prof Torbjörn Bäckström, PMDD research pioneer and Asarina Pharma CSO, will speak about the science and treatment of PMDD.
Asarina Pharma AB (publ) Interim Report, Q1 2019 released
(Stockholm May 20, 2019) Asarina Pharma CEO Peter Nordkild: “We have made a strong start to 2019. This Quarter we have strengthened our team and capabilities, yet still maintained strict financial management – leading to a solid cash position at the end of the First Quarter.”